Placebo haunts Cell Pathways

Placebo haunts Cell Pathways

Cell Pathways Inc. last week said it was baffled by the improvement of patients in the placebo arm of its Phase III trial of Prevatac exisulind in adenomatous polyposis coli, which is a non-remitting disease. While the company believes that the trial, rather than the compound, is flawed, investors are likely to remain wary until CLPA can show that its only

Read the full 654 word article

How to gain access

Continue reading with a
two-week free trial.